Glassman Wealth Services Fate Therapeutics Inc Transaction History

Glassman Wealth Services

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$2.02 - $5.04 $107 - $267	53 New	53 $0
Q4 2022 Feb 06, 2023	BUY	$9.86 - $23.83 $700 - $1,691	71 Added 1420.0%	76 $0
Q3 2022 Nov 09, 2022	SELL	$21.04 - $36.06 $147 - $252	-7 Reduced 58.33%	5 $0
Q2 2022 Aug 04, 2022	BUY	$17.78 - $42.39 $213 - $508	12 New	12 $0
Q4 2021 Feb 14, 2022	SELL	$47.84 - $64.34 $1,578 - $2,123	-33 Closed	0 $0
Q3 2021 Nov 10, 2021	BUY	$59.27 - $95.73 $1,778 - $2,871	30 Added 1000.0%	33 $2,000
Q2 2021 Aug 04, 2021	BUY	$67.25 - $92.52 $134 - $185	2 Added 200.0%	3 $0
Q1 2021 May 05, 2021	BUY	$72.16 - $117.4 $72 - $117	1 New	1 $0
Q3 2019 Nov 01, 2019	SELL	$15.47 - $22.5 $170 - $247	-11 Closed	0 $0
Q2 2019 Aug 08, 2019	BUY	$15.61 - $20.44 $171 - $224	11 New	11 $0

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $222M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Glassman Wealth Services, based on Form 13F filings with the SEC.

Stay updated on Glassman Wealth Services with notifications on news.